MedPal AI is a speculative, vertically integrated UK digital-health scale play where eMARx, robotic dispensing and GLP-1 growth could unlock substantial upside despite severe dilution and regulatory risk.
Overview
MedPal AI PLC has moved from a pre-revenue technology developer to an operating, vertically integrated UK healthcare provider. Its Health OS links wearable-data monitoring, Vertex AI-supported WhatsApp triage, human clinical validation, robotic dispensing and next-day delivery, allowing the company to capture economics across the healthcare workflow rather than relying on third-party pharmacies. Revenue began at £1,603,943 in the six months ended 28 February 2026, versus £nil previously, while prescription volumes rose from zero in October 2025 to a record 42,250 items in May 2026 and exceeded 250,000 cumulative prescriptions within nine months. **The principal near-term catalyst is pharmacy-level EBITDA breakeven at approximately 80,000 monthly items, guided for Q4 2026.** The July 2026 £5.00 million placing at £0.0350 per share, a 40% premium to the April placing, provided market validation but did not eliminate dilution risk. Optimo Research’s 41.57 GBp (£0.4157) target uses an 8.0x FY2027 EV-to-Sales multiple. The investment case is highly speculative: rapid growth, eMARx adoption and oral GLP-1 launches create substantial upside, but regulation, cash burn and further equity issuance remain material constraints.